Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWeight loss injections such as Mounjaro (tirzepatide) and Wegovy (semaglutide) are taken once a week, on the same day each week. That single weekly dose is the schedule set by the medicines' UK licences, and it applies regardless of which strength you are on. These are prescription-only medicines, so the exact schedule a prescriber sets for you may vary based on your individual assessment — but for most people, it is one injection, once every seven days. Mounjaro and Wegovy are the two GLP-1 class medicines currently licensed in the UK for weight management in adults.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The weekly rhythm of these injections is built into how the medicines work. Both tirzepatide and semaglutide have long half-lives, meaning a single dose keeps circulating in your system for roughly seven days. That design is deliberate: it keeps the medicine's effect on appetite and blood sugar regulation steady across the week, without the peaks and troughs you would get from a daily injection. The weight loss injection itself takes seconds, a small pre-filled pen pressed against the skin of your abdomen, thigh or upper arm.
The practical question most people ask is where the injection fits into a normal week. Many people choose a fixed day that is easy to remember, a Monday evening, a Sunday morning before the kettle goes on. Routine matters, and a consistent weekly anchor is the most reliable way to stay on schedule.
The NHS tirzepatide guidance and the equivalent semaglutide page both confirm the once-weekly schedule and give practical advice on what to do if you lose track of the day.
Here is the decision that trips people up. The frequency never changes: it is always once a week. What changes over time is the strength of the dose. Both Mounjaro and Wegovy start at a lower dose designed to let your body adjust (nausea is common early on, and the starter dose keeps that manageable) before the prescriber moves you up in steps, typically every four weeks, toward the dose that provides meaningful weight management. For Mounjaro, the schedule runs through 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and up to 15 mg. For Wegovy, the path runs from 0.25 mg up to 2.4 mg, and now up to 7.2 mg following a new MHRA-approved single-dose pen.
Dose increases are clinical decisions, not automatic. If you are considering starting treatment through a regulated online pharmacy, every dose change at nume requires a prescriber review, the same clinical oversight that applies to your initial assessment. You can read about how we approach that on our about page.
Understanding the difference between frequency (constant) and strength (increasing) helps you have a more useful conversation with whoever is prescribing for you. It also explains why the box in your fridge does not change shape every week, just the number printed on it.
Life gets in the way. A dose forgotten, a holiday that shifts your usual day, a week where the pen stayed in the gym bag and the gym bag stayed in the car. This is the most practical frequency question, and it has a structured answer. If fewer than four days have passed since your missed dose, most guidance suggests taking it as soon as you remember and then resuming your usual weekly day. If more than four days have elapsed, you skip that dose and carry on from your next scheduled day, you do not double up. The specifics of when and how to inject are always governed by your Patient Information Leaflet and your prescriber's instructions, not general internet advice.
Changing your day permanently is simpler. You can shift by a few days as long as you keep at least four days between any two injections. Again, the leaflet sets this out clearly, and your prescriber is the right person to check with if you are unsure. If you have questions between doses, our support team is available seven days a week.
Because these injections are taken weekly, the cost of treatment is generally quoted per four-week pen or per month. That framing is worth understanding before you compare prices across providers. A single Mounjaro pen contains four doses, so one pen covers roughly a month at any given strength. Wegovy pens are supplied as single-dose pre-filled pens, one per week.
For context on what private treatment typically costs and what a legitimate price includes, our treatment overview page covers the full picture, including what the MHRA's counterfeit warnings mean for anyone buying online. It is also worth knowing that the clinical review before every repeat order is part of what a properly run private service does, it is not a hurdle, it is the point. Frequency questions and dose-change decisions are discussed at those reviews.
If you are wondering whether a long NHS waiting list is the only alternative to going private, it is not. Eligible adults can access both Mounjaro and Wegovy through a regulated private pharmacy following a same-day clinical review by a GPhC-registered prescriber. Check your eligibility and start a free consultation to find out whether treatment is right for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.